Forecast Of The Day: Bristol-Myers Squibb’s Cardiovascular Drugs Revenue
What?
Trefis expects Bristol-Myers Squibb’s (NYSE:BMY) Cardiovascular Drugs Revenue to rise from $9.2 billion in 2020 to $11.4 billion in 2021 and to $12.6 billion in 2022.
Why?
- Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
- Is Bristol Myers Squibb Stock Undervalued At $50?
- Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level of $80?
- Which Stock Is A Better Healthcare Pick – Bristol Myers Squibb Or HCA?
- Will Bristol Myers Squibb Stock Rise Post Q1?
- Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?
We expect sales growth to be driven partly by Eliquis, an anticoagulant.
So What?
Although the Oncology segment remains the biggest driver of BMY’s revenues, we think that Cardiovascular drugs will play an increasing role in driving the company’s revenues and profits in the coming years.
See Our Complete Analysis For Bristol Myers Squibb
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams